Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis

G. R. D'Haens, W. J. Sandborn, G. Zou, L. W. Stitt, P. J. Rutgeerts, D. Gilgen, V. Jairath, P. Hindryckx, L. M. Shackelton, M. K. Vandervoort, C. E. Parker, C. Muller, R. K. Pai, O. Levchenko, Y. Marakhouski, M. Horynski, E. Mikhailova, N. Kharchenko, S. Pimanov, B. G. Feagan

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis'. Together they form a unique fingerprint.

Medicine & Life Sciences